Astellas Pharma (OTCMKTS:ALPMY) Hits New 52-Week Low at $9.15

Astellas Pharma Inc. (OTCMKTS:ALPMY) hit a new 52-week low on Tuesday . The company traded as low as $9.15 and last traded at $9.34, with a volume of 692432 shares. The stock had previously closed at $9.27.

Astellas Pharma Stock Performance

The company has a market capitalization of $16.90 billion, a P/E ratio of 24.49, a P/E/G ratio of 1.23 and a beta of 0.32. The company has a debt-to-equity ratio of 0.31, a current ratio of 0.91 and a quick ratio of 0.71. The stock’s 50 day simple moving average is $10.79 and its two-hundred day simple moving average is $11.68.

Astellas Pharma (OTCMKTS:ALPMY) last announced its earnings results on Monday, February 5th. The company reported $0.12 earnings per share for the quarter. Astellas Pharma had a net margin of 0.08% and a return on equity of 6.39%. The company had revenue of $2.86 billion during the quarter. As a group, research analysts expect that Astellas Pharma Inc. will post 0.35 earnings per share for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.